Investigation of FcRn‐Mediated Transepithelial Mechanisms for Oral Nanoparticle Delivery Systems
- 24 September 2021
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 4 (12), 2100145
- https://doi.org/10.1002/adtp.202100145
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872818)
This publication has 44 references indexed in Scilit:
- A review of current nanoparticle and targeting moieties for the delivery of cancer therapeuticsEuropean Journal of Pharmaceutical Sciences, 2013
- Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticlesAdvanced Drug Delivery Reviews, 2011
- Self‐Assembled pH‐Sensitive Nanoparticles: A Platform for Oral Delivery of Protein DrugsAdvanced Functional Materials, 2010
- Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRnProceedings of the National Academy of Sciences of the United States of America, 2008
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Critical nodes in signalling pathways: insights into insulin actionNature Reviews Molecular Cell Biology, 2006
- Caveosomes and endocytosis of lipid raftsJournal of Cell Science, 2003
- A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complexNature, 2002
- The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and releaseBiochemistry, 1993
- Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity.JCI Insight, 1986